Clinical Parkinsonism & Related Disorders (Jan 2024)

Antidiabetic drugs in Parkinson’s disease

  • Yoshajandith Aguirre-Vidal,
  • Sergio Montes,
  • Ana Carolina Mota-López,
  • Gabriel Navarrete-Vázquez

Journal volume & issue
Vol. 11
p. 100265

Abstract

Read online

This review explores the intricate connections between type 2 diabetes (T2D) and Parkinson’s disease (PD), both prevalent chronic conditions that primarily affect the aging population. These diseases share common early biochemical pathways that contribute to tissue damage. This manuscript also systematically compiles potential shared cellular mechanisms between T2D and PD and discusses the literature on the utilization of antidiabetic drugs as potential therapeutic options for PD. This review encompasses studies investigating the experimental and clinical efficacy of antidiabetic drugs in the treatment of Parkinson’s disease, along with the proposed mechanisms of action. The exploration of the benefits of antidiabetic drugs in PD presents a promising avenue for the treatment of this neurodegenerative disorder.

Keywords